Icosavax Mourns Sudden Passing of Tadataka Yamada, M.D. Chairman of the Company’s Board of Directors
August 05 2021 - 8:00AM
Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company
leveraging its innovative virus-like particle (VLP) platform
technology to develop vaccines against infectious diseases, with an
initial focus on life-threatening respiratory diseases, today
acknowledged the sudden passing of Tadataka (Tachi) Yamada, M.D.,
co-founder and Chairman of the Board of Icosavax, who died
unexpectedly on August 4, 2021.
“It is with great sadness that we share the news of our Chairman
and co-founder’s sudden passing. Tachi was a brilliant man, a
physician-scientist, and deeply committed to the cause of public
health,” said Adam Simpson, Chief Executive Officer of Icosavax,
Inc. “I had the honor not just of co-founding Icosavax with Tachi,
but working with him previously. We look forward to continuing to
advance Icosavax’s vaccine candidates, to help make a profound
impact on human health, as Tachi envisioned. On a personal level, I
will miss his friendship, his optimism and his dedication, losses
that I know are mitigated in some part by the enormous legacy he
leaves behind. Needless to say, the Board, leadership, and
employees of Icosavax offer their heartfelt condolences to Tachi’s
family and friends at this time.”
About Dr. Yamada
Dr. Yamada had a prolonged and successful career in public
health and the life sciences industry more broadly, having risen to
lead R&D efforts for both Takeda and GlaxoSmithKline. He also
was a former President of the Bill & Melinda Gates Foundation
Global Health Program. Earlier in his career he was Chief of the
Division of Gastroenterology and the Chair of the Department of
Internal Medicine at the University of Michigan in Ann Arbor. In
recognition of his contributions to medicine and science, he was
elected to membership in the National Academy of Medicine (US), the
Academy of Medical Sciences (UK) and the National Academy of
Medicine (Mexico). Dr. Yamada served as chair of the board of
directors at the Clinton Health Access Initiative and a member of
the National Academy of Medicine in addition to chair of several
biotech companies prior to his passing.
About Icosavax
Icosavax is a biopharmaceutical company leveraging its
innovative VLP platform technology to develop vaccines against
infectious diseases, with an initial focus on life-threatening
respiratory diseases. Icosavax’s VLP platform technology is
designed to enable multivalent, particle-based display of complex
viral antigens, which it believes will induce broad, robust, and
durable protection against the specific viruses targeted.
Icosavax’s pipeline includes vaccine candidates targeting
respiratory syncytial virus (RSV), human metapneumovirus (hMPV),
and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Icosavax was formed in 2017 to advance the breakthrough VLP
technology from the Institute for Protein Design at the University
of Washington with the goal to discover, develop, and commercialize
vaccines against infectious diseases. Icosavax exclusively licensed
the VLP technology for use in several fields, including RSV and
hMPV, from the University of Washington. For SARS-CoV-2, Icosavax
has a non-exclusive, worldwide (excluding South Korea) license from
the University of Washington that will convert to an exclusive
license in North America and Europe in 2025. Icosavax is located in
Seattle.
Contact:
For Media Only: Jessica Yingling, Ph.D.Little
Dog Communications Inc.jessica@litldog.com+1.858.344.8091
Icosavax Investor Contact:Laurence
WattsGilmartin Group,
LLClaurence@gilmartinir.com+1.619.916.7620
Icosavax (NASDAQ:ICVX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Icosavax (NASDAQ:ICVX)
Historical Stock Chart
From Apr 2023 to Apr 2024